MedPlus Health IPO opens for subscription: Does the pharma retailer have a pill for profit?

At the issue price, MedPlus would trade at 3.1x FY21 P/S & 40x FY21 EV/EBITDA, said Aditya Birla Capital, which has suggested investors with high-risk appetite to subscribe to the IPO.